| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential.
|
Nat Rev Drug Discov
|
2006
|
2.84
|
|
2
|
Kynurenine is an endothelium-derived relaxing factor produced during inflammation.
|
Nat Med
|
2010
|
2.12
|
|
3
|
Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure.
|
Hypertension
|
2007
|
1.84
|
|
4
|
Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase.
|
J Biol Chem
|
2003
|
1.61
|
|
5
|
Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling.
|
Circulation
|
2006
|
1.55
|
|
6
|
Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats.
|
Hypertension
|
2006
|
1.50
|
|
7
|
Stimulation of soluble guanylate cyclase prevents cigarette smoke-induced pulmonary hypertension and emphysema.
|
Am J Respir Crit Care Med
|
2014
|
1.48
|
|
8
|
NO- and haem-independent soluble guanylate cyclase activators.
|
Handb Exp Pharmacol
|
2009
|
1.45
|
|
9
|
Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension.
|
ChemMedChem
|
2009
|
1.36
|
|
10
|
Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase.
|
J Biol Chem
|
2010
|
1.34
|
|
11
|
Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation.
|
Circ Res
|
2009
|
1.29
|
|
12
|
The chemistry and biology of soluble guanylate cyclase stimulators and activators.
|
Angew Chem Int Ed Engl
|
2013
|
1.18
|
|
13
|
Early urinary and plasma biomarkers for experimental diabetic nephropathy.
|
Clin Lab
|
2012
|
1.15
|
|
14
|
Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models.
|
J Hypertens
|
2010
|
1.15
|
|
15
|
Residues stabilizing the heme moiety of the nitric oxide sensor soluble guanylate cyclase.
|
Eur J Pharmacol
|
2005
|
1.11
|
|
16
|
Nucleotidyl cyclase activity of soluble guanylyl cyclase α1β1.
|
Biochemistry
|
2011
|
1.05
|
|
17
|
Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis.
|
Arzneimittelforschung
|
2008
|
1.05
|
|
18
|
BAY 58-2667, a nitric oxide-independent guanylyl cyclase activator, pharmacologically post-conditions rabbit and rat hearts.
|
Eur Heart J
|
2009
|
1.04
|
|
19
|
Dimerization region of soluble guanylate cyclase characterized by bimolecular fluorescence complementation in vivo.
|
Mol Pharmacol
|
2007
|
1.04
|
|
20
|
Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme.
|
Am J Physiol Heart Circ Physiol
|
2011
|
1.04
|
|
21
|
Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in salt-sensitive Dahl rats.
|
PLoS One
|
2011
|
1.04
|
|
22
|
The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats.
|
PLoS One
|
2012
|
1.00
|
|
23
|
Identification of residues crucially involved in soluble guanylate cyclase activation.
|
FEBS Lett
|
2006
|
1.00
|
|
24
|
Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase.
|
Eur J Pharmacol
|
2003
|
0.99
|
|
25
|
Elevated plasma human urotensin-II-like immunoreactivity in ischemic cardiomyopathy.
|
Int J Cardiol
|
2004
|
0.98
|
|
26
|
The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction.
|
J Am Heart Assoc
|
2013
|
0.98
|
|
27
|
Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production.
|
Circulation
|
2002
|
0.97
|
|
28
|
Riociguat for the treatment of pulmonary hypertension.
|
Expert Opin Investig Drugs
|
2011
|
0.96
|
|
29
|
Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation.
|
Am J Respir Crit Care Med
|
2007
|
0.96
|
|
30
|
Pre-conditioning with the soluble guanylate cyclase activator Cinaciguat reduces ischaemia-reperfusion injury after cardiopulmonary bypass.
|
Eur J Cardiothorac Surg
|
2010
|
0.96
|
|
31
|
Cinaciguat, a soluble guanylate cyclase activator, augments cGMP after oxidative stress and causes pulmonary vasodilation in neonatal pulmonary hypertension.
|
Am J Physiol Lung Cell Mol Physiol
|
2011
|
0.95
|
|
32
|
NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy.
|
Br J Pharmacol
|
2006
|
0.95
|
|
33
|
Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide.
|
Am J Physiol Heart Circ Physiol
|
2012
|
0.95
|
|
34
|
Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart.
|
Hypertens Res
|
2009
|
0.90
|
|
35
|
Diabetic endothelin B receptor-deficient rats develop severe hypertension and progressive renal failure.
|
J Am Soc Nephrol
|
2006
|
0.90
|
|
36
|
Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure.
|
Circulation
|
2003
|
0.89
|
|
37
|
Effects of stimulation of soluble guanylate cyclase on diabetic nephropathy in diabetic eNOS knockout mice on top of angiotensin II receptor blockade.
|
PLoS One
|
2012
|
0.88
|
|
38
|
Insights into BAY 60-2770 activation and S-nitrosylation-dependent desensitization of soluble guanylyl cyclase via crystal structures of homologous nostoc H-NOX domain complexes.
|
Biochemistry
|
2013
|
0.88
|
|
39
|
BAY 41-2272 activates two isoforms of nitric oxide-sensitive guanylyl cyclase.
|
Biochem Biophys Res Commun
|
2002
|
0.88
|
|
40
|
A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide/cGMP pathway.
|
Anal Biochem
|
2005
|
0.88
|
|
41
|
Receptor binding assay for nitric oxide- and heme-independent activators of soluble guanylate cyclase.
|
Anal Biochem
|
2003
|
0.87
|
|
42
|
NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size.
|
Cardiovasc Res
|
2013
|
0.86
|
|
43
|
Tetrahydrobiopterin protects soluble guanylate cyclase against oxidative inactivation.
|
Mol Pharmacol
|
2012
|
0.86
|
|
44
|
Endothelin-1 overexpression restores diastolic function in eNOS knockout mice.
|
J Hypertens
|
2011
|
0.84
|
|
45
|
The soluble guanylyl cyclase activator bay 58-2667 selectively limits cardiomyocyte hypertrophy.
|
PLoS One
|
2012
|
0.84
|
|
46
|
Soluble guanylate cyclase: a potential therapeutic target for heart failure.
|
Heart Fail Rev
|
2013
|
0.83
|
|
47
|
Increased levels of laminin and collagen type VI may reflect early remodelling in patients with acute myocardial infarction.
|
Acta Cardiol
|
2009
|
0.83
|
|
48
|
Fluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living cells.
|
PLoS One
|
2011
|
0.83
|
|
49
|
The Rho kinase inhibitor azaindole-1 has long-acting vasodilator activity in the pulmonary vascular bed of the intact chest rat.
|
Can J Physiol Pharmacol
|
2012
|
0.82
|
|
50
|
Novel soluble guanylyl cyclase stimulator BAY 41-2272 attenuates ischemia-reperfusion-induced lung injury.
|
Am J Physiol Lung Cell Mol Physiol
|
2008
|
0.82
|
|
51
|
Effects of the sGC stimulator BAY 41-2272 are not mediated by phosphodiesterase 5 inhibition.
|
Circulation
|
2004
|
0.82
|
|
52
|
BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats.
|
Eur J Pharmacol
|
2010
|
0.82
|
|
53
|
Measuring oxidative burden and predicting pharmacological response in coronary artery disease patients with a novel direct activator of haem-free/oxidised sGC.
|
Atherosclerosis
|
2011
|
0.81
|
|
54
|
Increased serum levels of tissue inhibitor of metalloproteinase-1 in patients with acute myocardial infarction.
|
Int Heart J
|
2009
|
0.81
|
|
55
|
Analysis of erectile responses to BAY 41-8543 and muscarinic receptor stimulation in the rat.
|
J Sex Med
|
2012
|
0.81
|
|
56
|
Direct sGC activation bypasses NO scavenging reactions of intravascular free oxy-hemoglobin and limits vasoconstriction.
|
Antioxid Redox Signal
|
2013
|
0.81
|
|
57
|
Novel, selective indole-based ECE inhibitors: lead optimization via solid-phase and classical synthesis.
|
Bioorg Med Chem Lett
|
2005
|
0.81
|
|
58
|
Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis.
|
Am J Physiol Renal Physiol
|
2004
|
0.81
|
|
59
|
The soluble guanylate cyclase activator BAY 58-2667 protects against morbidity and mortality in endotoxic shock by recoupling organ systems.
|
PLoS One
|
2013
|
0.80
|
|
60
|
Relaxin is an independent risk factor predicting death in male patients with end-stage kidney disease.
|
Circulation
|
2004
|
0.79
|
|
61
|
The selective Rho-kinase inhibitor azaindole-1 has long-lasting erectile activity in the rat.
|
Urology
|
2013
|
0.78
|
|
62
|
Soluble guanylate cyclase agonists inhibit expression and procoagulant activity of tissue factor.
|
Arterioscler Thromb Vasc Biol
|
2009
|
0.78
|
|
63
|
Influence of cinaciguat on gastrointestinal motility in apo-sGC mice.
|
Neurogastroenterol Motil
|
2014
|
0.78
|
|
64
|
Soluble CD154 is a unique predictor of nonfatal and fatal atherothrombotic events in patients who have end-stage renal disease and are on hemodialysis.
|
J Am Soc Nephrol
|
2007
|
0.77
|
|
65
|
Attenuated response of L-type calcium current to nitric oxide in atrial fibrillation.
|
Cardiovasc Res
|
2013
|
0.77
|
|
66
|
Identification of acidic heterocycle-substituted 1H-pyrazolo[3,4-b]pyridines as soluble guanylate cyclase stimulators.
|
Bioorg Med Chem Lett
|
2013
|
0.77
|
|
67
|
Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors.
|
ChemMedChem
|
2008
|
0.77
|
|
68
|
Effects of different pulmonary vasodilators on arterial saturation in a model of pulmonary hypertension.
|
PLoS One
|
2013
|
0.77
|
|
69
|
Structure/activity relationships of (M)ANT- and TNP-nucleotides for inhibition of rat soluble guanylyl cyclase α1β1.
|
Mol Pharmacol
|
2014
|
0.76
|
|
70
|
Gender-dependent impact of risk factors for cardiovascular and non-cardiovascular mortality in end-stage renal disease patients on haemodialysis.
|
Kidney Blood Press Res
|
2008
|
0.76
|
|
71
|
Selective indole-based ECE inhibitors: synthesis and pharmacological evaluation.
|
ChemMedChem
|
2006
|
0.76
|
|
72
|
Receptor binding assay for NO-independent activators of soluble guanylate cyclase.
|
Methods Mol Biol
|
2013
|
0.76
|
|
73
|
Additional lack of iNOS attenuates diastolic dysfunction in aged ET-1 transgenic mice.
|
Can J Physiol Pharmacol
|
2008
|
0.75
|
|
74
|
New antithrombotics with an indazole structure.
|
Arch Pharm (Weinheim)
|
2004
|
0.75
|
|
75
|
Endothelin-1 Overexpression Improves Renal Function in eNOS Knockout Mice.
|
Cell Physiol Biochem
|
2015
|
0.75
|